The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.
FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
More from FDA News AlertsMore posts in FDA News Alerts »
- Coronavirus (COVID-19) Update: June 22, 2021
- Prairie Wolf Spirits, Inc. Issues Voluntary Nationwide Recall of Prairie Wolf Distillery Hand Sanitizer Packed in 16.9 Oz. and 20 Oz Bottles Because They Resemble Drink Containers
- Sanit Technologies Adds Label Clarification to Existing Voluntary Hand Sanitizer Recall
- FDA Approves First Oral Blood Thinning Medication for Children